2025-05-19-Jefferies-Oric（ORIC）_邀请与管理层的虚拟小组炉边谈话_7页_100kb

USA Biotechnology: ORIC Pharmaceuticals Equity Research Summary

Event Information

• Date: Wednesday, May 21, 2025
• Time: 4:00 PM - 5:00 PM EST
• Participating Management: Jacob Chacko (CEO), Dominic Piscitelli (CFO)
• Virtual Fireside Chat: Registration HREF HERE

Investment Recommendation

• Rating: BUY
• Price Target: $22.00 (+365% upside from current price)
• Current Price: $4.73

Analyst Notes

• Jefferies, ORIC's financial advisor, anticipates receiving compensation for investment banking services.
• PT blend of DCF and probability-adjusted EPS analyses.

Key Details

• Ticker: ORIC
• Market Cap: ~$336.0M
• Float: 60.7%
• Recent Price Range: $14.67 (52W High) to $3.90 (52W Low)

Company Overview

• Focus: Clinical-stage biopharma targeting glucocorticoid receptor (GCR) antagonism.
• Lead Program: ORIC-101 (Phase 1b trials in prostate cancer & solid tumors).

Key Clinical Pipelines:

• ORIC-944: Metastatic Prostate Cancer (mCRPC)
• ORIC-114: Non-Small Cell Lung Cancer (NSCLC)